|Bid||0.00 x 1100|
|Ask||0.00 x 1100|
|Day's range||340.30 - 345.31|
|52-week range||193.89 - 375.23|
|Beta (5Y monthly)||0.59|
|PE ratio (TTM)||36.40|
|Earnings date||31 Oct 2022 - 04 Nov 2022|
|Forward dividend & yield||2.16 (0.63%)|
|Ex-dividend date||31 Aug 2022|
|1y target est||383.54|
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Myriad Genetics' (MYGN) expansion across the globe, banking on myChoiceCDx test sales, seems impressive.
The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.